G-protein coupled receptor 124 (GPR124) in endothelial cells regulates vascular endothelial growth factor (VEGF)-induced tumor angiogenesis

Current Molecular Medicine

Volumn 14, Issue 4, 2014, Pages 543-554

  Wang, Y ^a,b   Cho, S G ^b,c   Wu, X ^a   Siwko, S ^b   Liu, M ^b,d  

^a HUNAN NORMAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c Kyung Hee University   (South Korea)

^d EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cancer; G protein coupled receptors (GPCR); Tumor; Vascular biology; Vascular endothelial growth factor (VEGF)

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 124; UNCLASSIFIED DRUG; VASCULOTROPIN; GPR124 PROTEIN, HUMAN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INTERACTION; CELL INVASION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CAPILLARY PERMEABILITY; CELL COMMUNICATION; CELL LINE; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALS; CAPILLARY PERMEABILITY; CELL COMMUNICATION; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904046106     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666140414205943     Document Type: Article

References (41)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
2. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007; 26: 489-502.
3. Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 2012; 114: 237-67.
4. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012; 12: 699-709.
5. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-71.
6. Pang X, Yi Z, Zhang J, et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 2010; 70: 1951-9.
7. Yi ZF, Cho SG, Zhao H, et al. A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells. Int J Cancer 2009; 124: 843-52.
8. Song Y, Dai F, Zhai D, et al. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis 2012; 15: 421-32.
9. Eliceiri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4: 915-24.
10. Ilic D, Kovacic B, McDonagh S, et al. Focal adhesion kinase is required for blood vessel morphogenesis. Circ Res 2003; 92: 300-7.
11. Eliceiri BP, Puente XS, Hood JD, et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 2002; 157: 149-60.
12. Abu-Ghazaleh R, Kabir J, Jia H, Lobo M, Zachary I. Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem J 2001; 360: 255-64.
13. Tavora B, Batista S, Reynolds LE, et al. Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med 2010; 2: 516-28.
14. Byzova TV, Goldman CK, Pampori N, et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 2000; 6: 851-60.
15. Ciccimaro E, Hevko J, Blair IA. Analysis of phosphorylation sites on focal adhesion kinase using nanospray liquid chromatography/multiple reaction monitoring mass spectrometry. Rapid Commun Mass Spectrom 2006; 20: 3681-92.
16. Carson-Walter EB, Watkins DN, Nanda A, et al. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001; 61: 6649-55.
17. Nanda A, Carson-Walter EB, Seaman S, et al. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res 2004; 64: 817-20.
18. Bagley RG, Rouleau C, Weber W, et al. Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy. Microvasc Res 2011; 82: 253-62.
19. Tomkowicz B, Rybinski K, Sebeck D, et al. Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biol Ther 2010; 9: 908-15.
20. Bagley RG, Honma N, Weber W, et al. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc Res 2008; 76: 180-8.
21. Davies G, Rmali KA, Watkins G, et al. Elevated levels of tumour endothelial marker-8 in human breast cancer and its clinical significance. Int J Oncol 2006; 29: 1311-7.
22. Rmali KA, Watkins G, Harrison G, et al. Tumour endothelial marker 8 (TEM-8) in human colon cancer and its association with tumour progression. Eur J Surg Oncol 2004; 30: 948-53.
23. Davies G, Cunnick GH, Mansel RE, Mason MD, Jiang WG. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis 2004; 21: 31-7.
24. Vallon M, Essler M. Proteolytically processed soluble tumor endothelial marker (TEM) 5 mediates endothelial cell survival during angiogenesis by linking integrin alpha(v)beta3 to glycosaminoglycans. J Biol Chem 2006; 281: 34179-88.
25. Vallon M, Aubele P, Janssen KP, Essler M. Thrombininduced shedding of tumour endothelial marker 5 and exposure of its RGD motif are regulated by cell-surface protein disulfide-isomerase. Biochem J 2012; 441: 937-44.
26. Danhier F, Le Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012; 9: 2961-73.
27. Yamamoto Y, Irie K, Asada M, et al. Direct binding of the human homologue of the Drosophila disc large tumor suppressor gene to seven-pass transmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein. Oncogene 2004; 23: 3889-97.
28. Cullen M, Elzarrad MK, Seaman S, et al. GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier. Proc Natl Acad Sci USA 2011; 108: 5759-64.
29. Kuhnert F, Mancuso MR, Shamloo A, et al. Essential regulation of CNS angiogenesis by the orphan G proteincoupled receptor GPR124. Science 2010; 330: 985-9.
30. Anderson KD, Pan L, Yang XM, et al. Angiogenic sprouting into neural tissue requires Gpr124, an orphan G proteincoupled receptor. Proc Natl Acad Sci USA 2011; 108: 2807-12.
31. Cho SG, Yi Z, Pang X, et al. Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res 2009; 69: 7062-70.
32. Cho SG, Li D, Stafford LJ, et al. KiSS1 suppresses TNFalpha-induced breast cancer cell invasion via an inhibition of RhoA-mediated NF-kappaB activation. J Cell Biochem 2009; 107: 1139-49.
33. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274: 9116-21.
34. Pistrosch F, Herbrig K, Oelschlaegel U, et al. PPARgammaagonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 2005; 183: 163-7.
35. Muller-Brusselbach S, Komhoff M, Rieck M, et al. Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice. EMBO J 2007; 26: 3686-98.
36. Piqueras L, Reynolds AR, Hodivala-Dilke KM, et al. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 63-9.
37. Biscetti F, Gaetani E, Flex A, et al. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 2008; 57: 1394-1404.
38. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol 1998; 184: 44-52.
39. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-73.
40. Le Boeuf F, Houle F, Huot J. Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 2004; 279: 39175-85.
41. Lamalice L, Houle F, Huot J. Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. J Biol Chem 2006; 281: 34009-20.